Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLE: S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857Phase 2Recruiting
- Sponsor
- Servier
- Start
- Nov 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of nivolumab + ipilimumab in developmental and epileptic encephalopathy (DEE), sponsored by Servier. Started Nov 2025; status: recruiting.
02
Drugs
nivolumab + ipilimumab
03
Conditions
developmental and epileptic encephalopathy (DEE)
Beyond the preview
Go deeper on NCT07227857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227857.